摘要
目的 综述帕博利珠单抗治疗非小细胞肺癌研究的评价方法及结果,为提高我国帕博利珠单抗相应经济学评价质量提供参考。方法 利用计算机检索中国期刊全文数据库、中文期刊全文数据库、万方数据知识服务平台、PUBMED、The Cochrane Library、Ovid Embase等中英文数据库,检索各数据库建库至2021年12月帕博利珠单抗经济性评价研究文献。按纳入排除标准筛选文献后提取信息,使用CHEERS质量评价表评估纳入文献质量,并对纳入文献的基本信息、模型、效用值、成本来源以及经济性研究结果进行描述性分析。结果 本研究共纳入7篇文献,目前帕博利珠单抗治疗非小细胞肺癌研究模型多采用马尔可夫模型与分区生存模型,多采用成本-效果分析、成本-效用分析两种方法。研究角度包括卫生体系、医疗保障支付方、国家卫生服务体系三个角度,因此成本主要考虑直接医疗成本,成本数据来源于米内网、药智网、KETNOTE-042等公开发表的资料等。效果值、效用值均使用质量调整生命年(quality-adjusted life years, QALYs)作为远期健康获益指标,数据来源于公开发表的资料。5篇文献结果显示帕博利珠单抗治疗非小细胞肺癌不具有经济性,仅2篇文献结果显示帕博利珠单抗治疗非小细胞肺癌具有经济性。结论 我国帕博利珠单抗经济性研究存在缺乏真实世界数据、缺少适宜我国的临床数据、模型不适宜等问题,未来相关学者可以借鉴我国的RWS数据建立模型,从不同角度出发开展药物经济学评价。参照我国药物经济学评价指南建立决策树-马尔可夫混合模型评估帕博利珠单抗经济性,企业可通过降价、慈善捐赠等方式获得药物经济性。
Objective This paper reviews the evaluation methods and results of the research on the treatment of non-small cell lung cancer with pabolizumab,and provides a reference for improving the quality of economic evaluation of pabolizumab in China.Methods Chinese and English databases such as CNKI,VIP,Wanfang database,PubMed,the Cochrane Library and Ovid EMBASE were searched by computer.The research literature on the economic evaluation of pabolizumab from the establishment of each database to December 2021 was searched.After selecting the literature according to the inclusion and exclusion criteria,extract the information,use the cheers quality evaluation form to evaluate the quality of the included literature,and make a descriptive analysis from the perspective of the basic information,model,utility value,cost source and economic research results of the included literature.Results seven literatures were included in this study.At present,the research models of pabolizumab in the treatment of non-small cell lung cancer mostly use Markov model and zonal survival model,and mostly use two methods of cost-effectiveness analysis and cost-effectiveness analysis.The research includes the perspective of the health system,the payer of medical security and the national health service system.Therefore,the cost mainly considers the direct medical cost,and the cost data comes from the publicly published materials such as mi nei.com,Yao zhi.com and ketnote.Quality adjusted life years(QALYs)is used as the long-term health benefit index for both effect value and utility value,and the data is from published data.The results of five literatures included in this study showed that pabolizumab was not economical in the treatment of non-small cell lung cancer,and only two literatures showed that pabolizumab was economical in the treatment of non-small cell lung cancer.Conclusion There are some problems in the economic research of pabolizumab in China,such as lack of real-world data,lack of clinical data suitable for China and inappropriate model.In the future,relevant scholars can learn from China's RWS data to establish models and carry out pharmacoeconomic evaluation from different angles.Referring to the evaluation guidelines of pharmacoeconomics in China,a decision tree Markov hybrid model is established to evaluate the economy of pabolizumab.Enterprises can obtain the drug economy through price reduction and charitable donation.
作者
安琪
查镜凯
徐伟
AN Qi;ZHA Jing-Kai;XU Wei(International Pharmaceutical Business School of China Pharmaceutical University,Nanjing 211198,China)
出处
《中国药物经济学》
2023年第2期5-10,共6页
China Journal of Pharmaceutical Economics
